New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
10:27 EDTTKMR, NNVC, BCRX, HEBMapp drug used to treat Ebola patients, CNN reports
A drug made by privately held Mapp Biopharmaceutical was used to treat the two Americans who contracted Ebola, CNN reports, citing a source familiar with details of the treatment. The experimental treatment called ZMapp had never been tried before in a human but had showed promise with monkeys, CNN adds. Shares of Tekmira (TKMR), NanoViricides (NNVC), BioCryst (BCRX) and Hemispherx (HEB) are moving higher in early trading after two Americans were flown home with Ebola. Reference Link
News For TKMR;NNVC;BCRX;HEB From The Last 14 Days
Check below for free stories on TKMR;NNVC;BCRX;HEB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
06:13 EDTTKMRTekmira to collaborate with international consortium researching Ebola
Subscribe for More Information
September 22, 2014
13:02 EDTTKMRTekmira surges on FDA authorization of TKM-Ebola for emergency use
Subscribe for More Information
12:57 EDTTKMRTekmira up 20% following FDA authorization of TKM-Ebola for emergency use
09:16 EDTTKMRTekmira establishes regulatory framework for emergency use of TKM-Ebola
Subscribe for More Information
08:49 EDTHEBHemispherx announces Alferon LDO primate research peer-reviewed publication
Hemispherx Biopharma announced a peer-reviewed publication entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus by Low Dose Natural Human IFN-á Administered to the Buccal Mucosa" in the current issue of Antiviral Research 2014. This publication is a collaborative project conducted at Viroclinics Biosciences BV, Rotterdam, an internationally recognized research facility for the study of influenza viruses. The biohazard laboratories are directed by Prof. Albert D. M. E. Osterhaus, an internationally known virologist specializing in the study of pandemic influenza. Highly pathogenic avian influenza A virus is endemic in wild birds in Asia and the Middle East, causing disease and transmissibility in domestic poultry. Infection of humans with H5N1 is associated with a high mortality rate due to an alveolar destructive primary viral pneumonia frequently expressed clinically as acute respiratory distress syndrome.
September 18, 2014
12:08 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
BioCryst announced that the National Institute of Allergy and Infectious Diseases exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2M increase to the existing development contract. The contract modification and the two additional options exercised represent up to $4M to BioCryst in order to accelerate the development of BCX4430 as a treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. NIAID, part of the National Institutes of Health, granted this five year term contract to BioCryst in September 2013. Approximately $19.9M of funding has been awarded to date under the contract. With this additional award, the BCX4430 development contract has been increased in value to $26.3M, if all options are exercised. This project is funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C.
September 17, 2014
15:02 EDTTKMRCongressman questions why FDA hasn't moved on Ebola drug, The Hill says
Republican Congressman Michael Burgess said he was "bewildered" as to why the FDA continues to have a hold on Tekmira's TKS-Ebloa drug, a treatment for Ebola, according to The Hill. However, Democratic Congresswoman Betty McCollum warned against using Africa as a "testing ground" for drugs that haven't been property screened, the website noted. Reference Link
September 15, 2014
08:44 EDTHEBHemispherx Ampligen induces cross-reactive antibody formation
Subscribe for More Information
September 11, 2014
10:20 EDTTKMRNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
September 10, 2014
08:35 EDTHEBHemispherx expands Ebola collaborative research agreement with governments
Hemispherx Biopharma announced that it expanded its Collaborative Research Agreement to test Alferon, the only multi-species, natural alpha interferon, or IFN, commercially approved in the U.S. and Ampligen®, an experimental drug, to be evaluated against the deadly Ebola virus also under the DEA, or Data Exchange Agreement, Annex for Medical Preparedness and Bio-Defense Agreement between the Swiss Surgeon General and the US Department of Defense. The World Health Organization has warned that "The Ebola outbreak will affect more than 20,000 people in West Africa and might spread to more countries, indicating a clinical emergency all over the world."
September 9, 2014
07:07 EDTNNVCNanoViricides designs, commences synthesis of ebola drug candidates
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use